Clinical trials located in

Tychy

Tychy city is located in Poland. Currently, 11 clinical trials are being conducted in this city.

Tychy, located in southern Poland, is renowned for its brewing heritage, with the Tyskie Brewery being a pivotal part of the city’s identity since the 17th century. This city, established in the 15th century, has evolved into a significant industrial and cultural hub. Tychy is also notable for its modernist architecture from the 1960s and 1970s, particularly the unique residential districts designed during the communist era. The city’s commitment to green spaces is evident in its numerous parks and the large Paprocany Lake, a popular recreational area. Additionally, Tychy is home to the Fiat Auto Poland factory, one of the largest automotive manufacturing plants in Poland.

  • Evaluating a dual anticoagulant therapy for patients with atrial fibrillation and acute coronary syndrome after percutaneous coronary intervention

    This study focuses on patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) who have undergone a procedure called percutaneous coronary intervention (PCI). The therapy being tested involves a combination of drugs to prevent blood clots and manage heart health after PCI.

    Patients with both AF and ACS face a challenge: preventing clots while avoiding excessive bleeding. Standard practice often includes three drugs: an oral anticoagulant (OAC) to prevent stroke, aspirin, and clopidogrel. However, using all three drugs together can lead to a high risk of bleeding within a year.

    The study aims to find out if using just two drugs—dabigatran and ticagrelor—can be as safe and effective as the standard three-drug therapy. This approach is called a dual anticoagulant regimen. Participants in the study will be men and women aged 18 and older who have nonvalvular AF and have successfully undergone PCI for ACS. They will be randomly assigned to one of two groups: one group will receive dabigatran and ticagrelor, while the other group will receive dabigatran, clopidogrel, and aspirin. The treatment will last for 12 months.

    The main goal of the study is to see if the dual therapy is as good as the triple therapy in preventing major bleeding and cardiovascular events like heart attacks and strokes. The study also looks at other outcomes, such as death and the need for additional heart procedures. This research will provide important information about a new treatment strategy that could improve safety and effectiveness for patients with AF and ACS who undergo PCI.

  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    • placebo
    • Ravulizumab
  • Studying the safety and effectiveness of a new drug for ulcerative colitis

    This study focuses on examining a drug called ABBV-668, administered in oral capsules, to evaluate its safety and effectiveness in the treatment of adults with ulcerative colitis, a gastrointestinal disease characterized by bleeding and inflammation in the large intestine. About 40 participants will take the capsules twice a day for 16 weeks. After this treatment period, doctors will continue to monitor participants for an additional month. The study involves visiting a doctor more often than usual, carefully checking for potential side effects, and asking participants-specific questions. To measure changes in participants’ condition, doctors will use a special scoring system.

    • ABBV-668- new potential medication for inflammatory bowel diseases
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    • Ozanimod
  • Exploring the effect and safety of a new treatment for Severe Ulcerative Colitis

    This clinical trial aims to explore the potential of NX-13, a new oral medication, in providing relief to adults suffering from moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the digestive tract, leading to discomfort and other debilitating symptoms. The study is designed to test two different doses of NX-13, 250mg and 750mg, comparing them with a placebo to determine the medication’s effectiveness in managing the symptoms of this condition.

    Participants in the study will be carefully monitored to assess how well NX-13 controls the inflammation and symptoms associated with ulcerative colitis, and to ensure the safety and tolerability of the medication. The study also aims to understand the long-term impacts of the medication, with an extension period included to gather more comprehensive data on its sustained effects.

    • Amelenodor/NX-13
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.